Coronary restenosis

Acta Cardiologica Sinica

Volumn 21, Issue 4, 2005, Pages 177-189

  Chang, Chao Chien ^a   Ong, Eng Thiam ^a  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Coronary restenosis; Pathophysiology and molecular mechanism of restenosis

Indexed keywords

ANGIOPLASTY; BRACHYTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG ELUTING STENT; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVASCULARIZATION; REVIEW;

EID: 33644921466     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Bauters C, Isner JM. The biology of restenosis. In: Topol EJ, Ed. Textbook of Cardiovascular Medicine. Philadelphia, Pennsylvania: Lippincott-Raven; 1998:2465-90.
2. Gruntzig AR. Transluminal dilation of coronary artery stenosis. Lancet 1978;1:263.
3. Holmes DR, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53(suppl C):77-81.
4. Cohen EA, Sykora K, Kimball BP, et al. Clinical outcome of patients more than one year following randomization in the Canadian Coronary Atherectomy Trial. Can J Cardiol 1997;13: 825-30.
5. Cummins FE, Nonweiler JM, Ninneman RW. Percutaneous excimer laser coronary angioplasty: results of one center in a multi-center investigation. J Clin Laser Med Surg 1992;10:171-5.
6. Levin TN, Holloway S, Feldman T. Acute and late clinical outcome after rotational atherectomy for complex coronary disease. Cathet Cardiovasc Diagn 1998;45:122-30.
7. Indolfi C, Coppola C, Torella D, et al. Gene therapy for restenosis after balloon angioplasty and stenting. Cardiol Rev 1999;7:324-31.
8. Indolfi C, Torella D, Coppola C, et al. Rat carotid artery dilation by PTCA balloon catheter induces neointimal formation in presence of IEL rupture. Am J Physiol 2002;283:H760-H767.
9. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
10. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
11. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43.
12. Miano JM, Vlasic N, Tota RR, Stemerman MB. Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol 1993;142:715-24.
13. Riessen R, Wight TN, Pastore C, et al. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 1996;93:1141-7.
14. Ward MR, Tsao PS, Agrotis A, et al. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration. Arterioscler Thromb Vasc Biol 2001;21:208-13.
15. Wilcox JN, Waksman R, King SB, Scott NA. The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Oncol Biol Phys 1996;36:789-96.
16. Pickering JG, Ford CM, Chow LH. Evidence for rapid accumulation and persistently disordered architecture of fibrillar collagen in human coronary restenosis lesions. Am J Cardiol 1996;78:633-7.
17. Indolfi C, Chiariello M, Avvedimento EV. Selective gene therapy of proliferative disorders: sense and antisense. Nat Med 1996;6:634-5.
18. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. Inhibition of cellular RAS prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995;6:541-5.
19. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. In vivo gene transfer: prevention of neointimal formation by inhibition of mitogen-activated protein kinase kinase. Basic Res Cardiol 1997;92:378-84.
20. Indolfi C, Avvedimento EV, Di Lorenzo E, et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med 1997;3:775-7.
21. Indolfi C, Di Lorenzo E, Rapacciuolo A, et al. 8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointimal formation induced by balloon injury in vivo. J Am Coll Cardiol 2000;36:288-93.
22. Boehm M, Nabel EG. Cell cycle and cell migration: new pieces to the puzzle. Circulation 2001;103:2879-81.
23. Nabel EG. CDKs and CKIs: molecular targets for tissue remodelling. Nat Rev Drug Discov 2002;1:587-98.
24. Boehm M, Yoshimoto T, Crook MF, et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 2002;21:3390-401.
25. Ophascharoensuk A, Fero ML, Hughes J, et al. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 1998;4:575-80.
26. Tanner FC, Boehm M, Akyurek LM, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000;101:2022-5.
27. Indolfi C, Stabile E, Coppola C, et al. Membrane-bound protein kinase A inhibits smooth muscle cell proliferation in vitro and in vivo by amplifying c-AMP-PKA signals. Circ Res 2001;88:319-24.
28. Kuntz RE, Gibson CM, Nobuyoshi M, Bairn DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
29. Safian RD, McCabe CH, Sipperly ME, et al. Initial success and long term follow-up of percutaneous transluminal coronary angioplasty in chronic total occlusions versus conventional stenoses. Am J Cardiol 1988;61:23G-28G.
30. Violaris AG, Melkert R, Herrman JP, Serruys PW. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis. Circulation 1996;93:889-97.
31. Platko WP, Hollman J, Whitlow PL, Franco I. Percutaneous transluminal angioplasty of saphenous vein graft stenosis: long-term follow-up. J Am Coll Cardiol 1989;14:1645-50.
32. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998;32:1610-8.
33. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991;18:647-56.
34. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-93.
35. Bourassa MG, Lesperance J, Eastwood C, et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991;18:368-76.
36. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998;97:147-54.
37. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PIA1/PIA2 and coronary risk: a meta-analysis. Thromb Haemost 2001;85:626-33.
38. Ortlepp JR, Hoffmann R, Killian A, et al. The 4G/5G promoter polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol 2001;24:585-91.
39. Roguin A, Hochberg I, Nikolsky E, et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 2001;87:330-2.
40. Myler RK, Shaw RE, Stertzer SH, et al. Recurrence after coronary angioplasty. Cathet Cardiovasc Diagn 1987;13:77-86.
41. Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999;100:1616-22.
42. Mizuno O, Ikeda U, Hojo Y, et al. Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty. Cardiology 2001;95:84-9.
43. Gorge G, Ge J, Erbel R. Role of intravascular ultrasound in the evaluation of mechanisms of coronary interventions and restenosis. Am J Cardiol 1998;81:91-5.
44. Arakawa K, Isoda K, Sugiyabu Y, et al. Intimal proliferation after stenting reflected by increased stent-to-vessel cross-sectional area ratio: serial intravascular ultrasound study. J Cardiol 1998;32:379-89.
45. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
46. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
47. Gordon PC, Gibson CM, Cohen DJ, et al. Mechanisms of restenosis and redilation within coronary stents: quantitative angiographic assessment. J Am Coll Cardiol 1993;21:1166-74.
48. Scott NA, Crocker IR, Yin Q, et al. Inhibition of vascular cell growth by X-ray irradiation: comparison with gamma radiation and mechanism of action. Int J Radiat Oncol Biol Phys 2001;50:485-93.
49. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000;102:951-8.
50. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y betaradiation versus placebo control for treatment of in-stent restenosis. Circulation 2002;106:1090-6.
51. Waksman R, Raizner AE, Yeung AC, et al. Use of localized intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomized controlled trial. Lancet 2002;359:551-7.
52. Verin V, Popowski Y, de Bruyne B, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 2001;344:243-9.
53. Teirstein PS, Kuntz RE. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. Circulation 2001;104:2620-6.
54. Teirstein PS, Massullo V, Jani S, et al. Three-year clinical and angiographic follow-up after intracoronary radiation. Circulation 2000;101:360-5.
55. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2001;101:2165-71.
56. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001;103:2332-5.
57. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-6.
58. Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002;106:776-8.
59. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;347:561-6.
60. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: Drug-eluting stents: Part I. Circulation 2003;107:2274-9.
61. Park S-J, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
62. Gregg WS, Stephen GE, David AC, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
63. Swanson N, Hogrefe K, Javed Q, et al. Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelization and intimal hyperplasia. J Invasive Cardiol 2003;15:688-92.
64. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine- coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Cathet Cardiovasc Intervent 2002;57:266-71.
65. Krishnankutty S, Chiu T, Mullen W, et al. Mechanisms of estrogen induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995;26:807-14.
66. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res 2003;93:399-405.
67. Kutryk MJ, vanDortmont LM, deCrom RP, et al. Seeding of intravascular stents by the xenotransplantation of genetically modified endothelial cells. Semin Interv Cardiol 1998;3:217-20.
68. Gomes D, Louedec L, Plissonnier D, et al. Endoluminal smooth muscle cell seeding limits intimal hyperplasia. J Vasc Surg 2001;34:707-15.